封面
市場調查報告書
商品編碼
1454151

全球癌症腫瘤分析市場規模、佔有率、成長分析(按技術、癌症類型)- 產業預測,2024-2031 年

Global Cancer Tumor Profiling Market Size, Share, Growth Analysis, By Technology(Breast cancer, Lung cancer), By Cancer type(genomic biomarker, protein biomarker) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

癌症腫瘤分析的全球市場規模預計在 2022 年達到 107.3 億美元,從 2023 年的 118.7 億美元成長到 2031 年的 265.7 億美元,預測期內(2024-2031 年)複合年成長率為 10.6%。

推動癌症腫瘤分析市場的關鍵因素是全球癌症患者數量的增加以及生物標記在腫瘤分析中的應用。由於癌症研究、資助計劃和技術開發投資的增加,癌症腫瘤分析市場正在擴大。對於市場參與企業來說,照護現場和個人化醫療的擴展預計將在未來幾年提供重大機會。

預計 2020-2021 年 COVID-19 大流行不會對癌症腫瘤分析產業產生重大影響。由於採取了針對病毒的預防措施,COVID-19 大流行顯著減少了癌症檢測和診斷。蛋白質體學、磊晶、代謝體學和基因組學是癌症腫瘤分析市場預測期內的細分領域。其中,基因組學預計年複合成長率最高(19.7%)。此方法確定整個基因組內的基因是異常還是正常。它用於闡明基因的特徵。基因可以透過突變異常發育並幫助癌細胞生存。一種有前途的識別和研究癌症的方法被稱為癌症腫瘤分析,它檢查腫瘤型態、代謝和階段的變化。

目錄

執行摘要

  • 市場概況
  • 繁榮與衰落

調查方法

  • 資訊採購
  • 次要和主要資料來源
  • 市場規模估算
  • 市場假設與限制

母市場分析

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務

主要市場考察

  • 技術分析
  • 價格分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • Start-Ups分析
  • 原料分析
  • 創新矩陣
  • 研發線產品分析
  • 總體經濟指標
  • 主要投資分析
  • 關鍵成功因素
  • 競爭程度

市場動態及展望

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 監管環境
  • 波特的分析
  • 對未來中斷的特殊考慮

全球癌症腫瘤分析市場:依技術分類

  • 市場概況
  • 乳癌
  • 肺癌
  • 大腸直腸癌

全球癌症腫瘤分析市場:依癌症類型分類

  • 市場概況
  • 基因生物標記
  • 蛋白質生物標記

癌症腫瘤分析的全球市場規模:按地區

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東/非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲地區

競爭格局

  • 前5名企業對比
  • 主要企業市場定位(2021年)
  • 主要市場參與者所採取的策略
  • 關鍵成功策略
  • 近期市集活動
  • 主要企業市場佔有率(2021年)

主要企業簡介

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN NV
  • F. Hoffmann-La Roche AG
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Personal Genome Diagnostics Inc.
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • NanoString Technologies, Inc.
  • Genomic Health, Inc.
  • Adaptive Biotechnologies Corporation
  • Caris Life Sciences
  • Becton, Dickinson and Company
  • PerkinElmer, Inc.
  • Natera, Inc.
  • Oxford Nanopore Technologies
  • Biocartis Group NV
  • ArcherDX, Inc.
  • Sysmex Corporation
簡介目錄
Product Code: SQMIG35G2114

Global Cancer Tumor Profiling Market size was valued at USD 10.73 billion in 2022 and is poised to grow from USD 11.87 billion in 2023 to USD 26.57 billion by 2031, at a CAGR of 10.6% during the forecast period (2024-2031).

The main drivers propelling the market for cancer detection and treatment products are the global increase in cancer cases and the application of biomarkers in tumor profiling. The market for cancer and tumor profiling has expanded as a result of increased investments in cancer research, funding programs, and technology developments. For market participants, the expansion of point-of-care diagnostics and personalized medicine is anticipated to present substantial potential over the next years.

The COVID-19 pandemic in 2020-2021 is not anticipated to have a major effect on the cancer/tumor profiling industry. As a result of precautions made to guard against the virus, the COVID-19 epidemic has significantly reduced the amount of cancer testing and diagnoses. Proteomics, epigenetics, metabolomics, and genomics are the segments of the cancer/tumor profiling market that will be included in the forecast period. Of these, genomics is anticipated to have the greatest compound annual growth rate (19.7%). The method establishes if a gene within the entire genome is aberrant or normal. It is used to characterize genes. Genes develop abnormally due to mutations, which can aid in the survival of cancer cells. A promising method for identifying and researching cancer is cancer tumor profiling, which looks for alterations in tumor shape, metabolism, and stage.

Top-down and bottom-up approaches were used to estimate and validate the size of Global Cancer Tumor Profiling Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Logistics Automation Market Segmental Analysis

The market for cancer tumor profiling is divided into segments based on according to application, biomarker, cancer kind, and technology. On the other hand, technology is divided into categories such as microarrays, mass spectrometry, in-situ hybridization, polymerase chain reaction, next-generation sequencing, and immunoassays.Breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and other cancer types are divided into different categories. Protein biomarkers and genetic biomarkers are the two categories of biomarkers. Application is divided into two categories: research and biomarker identification. The market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Drivers of Global Cancer Tumor Profiling Market

One of the main factors driving market expansion in the overall cancer/tumor profiling industry is the rise in cancer incidences. Numerous causes contribute to the rising incidence of cancer. The disease is broad and complex, with multiple etiologies. The incidence of cancer is influenced by factors such as aging populations, increasing population sizes, and shifting rates of certain cancer causes.

Restraints in Global Cancer Tumor Profiling Market

In the cancer and tumor profiling industry, technical problems with sample collection and storage are impeding market expansion. A rapidly expanding area of medicine called "personalized medicine" is revolutionizing the diagnosis, categorization, and management of numerous illnesses. The way diseases are treated is already significantly changing as a result of the widespread adoption of this strategy in clinical practice. Oncology is one field where recent advancements in cancer treatment are very noticeable. Their associated risks may impede market expansion.

Market Trends of Global Cancer Tumor Profiling Market

The integration of omics data and developments in liquid biopsy tests are anticipated to drive the greatest compound annual growth rate (CAGR) in the cancer/tumor profiling market over the projected period. The topic of personalized medicine is a rapidly expanding area of healthcare study that is revolutionizing the diagnosis, classification, and treatment of diseases. It is currently utilized to treat a wide range of illnesses and has entered the mainstream of clinical practice. Oncology is one field where the advancements in cancer treatment are most noticeable.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Cancer Tumor Profiling Market by Technology

  • Market Overview
  • Breast cancer
  • Lung cancer
  • Colorectal cancer

Global Cancer Tumor Profiling Market by Cancer type

  • Market Overview
  • genomic biomarker
  • protein biomarker

Global Cancer Tumor Profiling Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Illumina, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Myriad Genetics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Personal Genome Diagnostics Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Foundation Medicine, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Guardant Health, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NanoString Technologies, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genomic Health, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adaptive Biotechnologies Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Caris Life Sciences
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PerkinElmer, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Natera, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oxford Nanopore Technologies
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biocartis Group NV
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ArcherDX, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sysmex Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments